Cargando…

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma

Malignant pleural mesothelioma (MPM) is a fatal cancer type that affects the membranes lining the lungs, and is causally associated with asbestos exposure. Until recently, the first-line treatment consisted of a combination of chemotherapeutics that only had a limited impact on survival, and had not...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rovers, Sophie, Janssens, Annelies, Raskin, Jo, Pauwels, Patrick, van Meerbeeck, Jan P., Smits, Evelien, Marcq, Elly
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945074/ https://www.ncbi.nlm.nih.gov/pubmed/35327475 http://dx.doi.org/10.3390/biomedicines10030673

Ejemplares similares

Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression
por: Marcq, Elly, et al.
Publicado: (2019)

External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma
por: Janssens, Eline, et al.
Publicado: (2022)

The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
por: Marcq, Elly, et al.
Publicado: (2021)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?
por: Siozopoulou, Vasiliki, et al.
Publicado: (2021)

Recent developments in the treatment of small cell lung cancer
por: Hiddinga, Birgitta I., et al.
Publicado: (2021)

Headspace Volatile Organic Compound Profiling of Pleural Mesothelioma and Lung Cancer Cell Lines as Translational Bridge for Breath Research
por: Janssens, Eline, et al.
Publicado: (2022)

Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma
por: Rondon, Lizbeth, et al.
Publicado: (2023)

NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects
por: Siozopoulou, Vasiliki, et al.
Publicado: (2021)

Surgical series in mesothelioma: navigating between biases
por: Raskin, Jo, et al.
Publicado: (2023)

New Implications of Patients’ Sex in Today’s Lung Cancer Management
por: Raskin, Jo, et al.
Publicado: (2022)

The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
por: Borgeaud, Maxime, et al.
Publicado: (2023)

Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma
por: Hylebos, Marieke, et al.
Publicado: (2017)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
por: Chiang, Eugene Y, et al.
Publicado: (2022)

Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis
por: Schillebeeckx, Eline, et al.
Publicado: (2021)

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer
por: Maas, Ralph Ja, et al.
Publicado: (2020)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Chemotherapy for malignant pleural mesothelioma: past results and recent developments
por: Tomek, S, et al.
Publicado: (2003)

Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
por: Kim, Roger Y., et al.
Publicado: (2021)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

KRAS signaling in malignant pleural mesothelioma
por: Marazioti, Antonia, et al.
Publicado: (2021)

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
por: van Haarst, J M W, et al.
Publicado: (2002)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Expression of the immune checkpoint receptor TIGIT in seminoma
por: Hinsch, Andrea, et al.
Publicado: (2019)

Update in TIGIT Immune-Checkpoint Role in Cancer
por: Annese, Tiziana, et al.
Publicado: (2022)

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
por: Hotta, Katsuyuki, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis
por: Gemelli, Maria, et al.
Publicado: (2022)

Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
por: Versteven, Maarten, et al.
Publicado: (2018)

Cancer in the time of COVID-19: expert opinion on how to adapt current practice
por: Raskin, Jo, et al.
Publicado: (2020)

Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
por: Woodard, Gavitt A., et al.
Publicado: (2020)

Thoracoscopy in Pleural Malignant Mesothelioma Diagnosis
por: Tassi, G. F., et al.
Publicado: (1997)

Imaging in staging of malignant pleural mesothelioma
por: Truong, Mylene T, et al.
Publicado: (2004)

Hedgehog Signaling in Malignant Pleural Mesothelioma
por: Felley-Bosco, Emanuela, et al.
Publicado: (2015)

Targeting YAP in malignant pleural mesothelioma
por: Zhang, Wen‐Qian, et al.
Publicado: (2017)

Multimodality treatment of malignant pleural mesothelioma
por: Berzenji, Lawek, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g5oonch0d3do7t1174q6vmmf50